Bio Elpida, your CDMO for Immunotherapy
Immuno-modulator, Bioproducts, Biomarkers

Bio Elpida is a CDMO company that develop and manufacture immunotherapy approaches using:
  • Immunomodulators
  • Bioproducts / Biomarkers:
  • Monoclonal antibodies
  • Other Immunoproteins

These approaches are used for various indications, especially for some cancer indications.

Especially, Bio Elpida produced IMM-101, a heat-killed whole cell preparation of Mycobacterium obuense that was used as an adjunctive immunotherapy for pancreatic cancer by Immodulon Therapeutics Ltd., leading to promising results in phase II trial. Read more…

A therapeutic approach which goal is to modulate the immune response

The principle of immunotherapy is to modify the immune response of a patient: induction, down-regulation or re-regulation of the immune system.

Bio Elpida

Founded in 2009, Bio Elpida is a Biotechnology Contract Development and Manufacturing Company specialised in the development and manufacturing of innovative cell therapies.

The expertise of the company covers 3 areas:
In these areas, Bio Elpida offers services that include:
Bio Elpida is the first French laboratory certified by the French Health Authorities (MSNA) as a Pharmaceutical Company and authorised to manufacture Active Pharmaceutical Ingredients for experimental biological pharmaceuticals.

Bio Elpida - 97 allée Alexandre Borodine - Bâtiment 5 Cèdre 1 - 69800 Saint Priest - FRANCE - Phone: +33 (0)4 78 47 02 70 - Mail: infos@bio-elpida.com
© Bio Elpida. All Rights Reserved - Legal information - Web site by: Estium-Concept
  • Your CDMO for
    Innovative Therapy
    SEARCH
    INNOVATE
    ACHIEVE
  • Your CDMO for
    Innovative Therapy
    SEARCH
    INNOVATE
    ACHIEVE
  • Your CDMO for
    Innovative Therapy
    SEARCH
    INNOVATE
    ACHIEVE
  •  
  •  
  •